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Nonsteroidal Anti-Inflammatory Drugs and Lung Cancer
Risk: A Population-Based Case Control Study
Richard J. Wall, MD, MPH,* Yu Shyr, PhD,† and Walter Smalley, MD, MPH‡
Background: It remains unknown whether nonsteroidal anti-in-
flammatory drugs (NSAIDs) confer a protective effect against lung
cancer development. We examined the relationship between NSAID
exposure and subsequent lung cancer development in a large state-
wide, population-based cohort.
Design: Nested case-control study in the Tennessee Medicaid pop-
ulation from 1990 to 2000.
Methods: Lung cancer cases were identified using a statewide
computerized claims database. Each time a case was identified, age-
and sex-matched controls were randomly selected from the available
source population. A detailed pharmacy database quantified nonste-
roidal anti-inflammatory drug (NSAID) exposure during the 5 years
before cancer diagnosis, and conditional logistic regression was used
to examine the relationship between NSAID exposure and lung
cancer development. Identical analyses were repeated in a subpopu-
lation of high-risk individuals with chronic obstructive pulmonary
disease (COPD).
Results: 303,399 persons were enrolled in the study population.
During 1.9 million person-years of follow-up (median 6.3 years per
person), 3,370 lung cancer cases were identified. Among those ever
using NSAIDs, the adjusted odds ratio of developing lung cancer
was 1.03 (95% confidence interval: 0.94–1.12). Among those using
24 months of NSAIDs in the 5 years before lung cancer diagnosis,
the adjusted odds ratio for lung cancer was 0.96 (95% confidence
interval: 0.82–1.11), and no protective effect was demonstrated in
any NSAID exposure stratum. Similarly, among the 2519 high-risk
individuals with chronic obstructive pulmonary disease, no signifi-
cant protective effect from NSAIDs was noted.
Conclusion: This large statewide, population-based study did not
demonstrate a protective effect of NSAIDs on lung cancer develop-
ment in either the general or high-risk chronic obstructive pulmo-
nary disease populations.
Key Words: Epidemiology, Lung neoplasm, Medicaid, Nonsteroidal
anti-inflammatory agents.
(J Thorac Oncol. 2007;2: 109–114)
Lung cancer is the leading cause of cancer deaths in theUnited States, killing 162,000 people annually and ulti-
mately accounting for nearly 29% of all cancer mortality.1
Despite advances in the knowledge and treatment of lung
cancer, the overall 5-year survival rate for newly diagnosed
cases is a sobering 15%.2 In addition, the financial burden
from this illness on the health care system is enormous. In
2002, 160,000 hospitalizations were attributed to lung cancer,
surpassing even colorectal cancer.3
Evidence that the use of nonsteroidal anti-inflammatory
drugs (NSAIDs) might be associated with a decreased risk of
colon cancer4 has generated considerable optimism that these
medications might also prevent various other cancers.
NSAIDs inhibit the cyclooxygenase (COX) enzymes respon-
sible for arachidonic acid metabolism, thereby disrupting
prostaglandin synthesis.5 Although the mechanistic details
are not yet fully understood, many researchers believe that
NSAIDs prevent colorectal cancer through altered angiogen-
esis or apoptosis.6
Previous studies examining the relationship between
NSAID use and lung cancer development have been conflict-
ing. Several studies showed a protective effect from NSAID
use on the incidence of lung cancer,7–11 but others have failed
to find a statistically significant protective effect.12–19 In
addition, generalizability of the positive studies is limited
because the protective effect was only seen in a pathologic
subset of lung cancers,7 a tertiary referral hospital popula-
tion,8,9 or a single gender.10,11 Although a recent meta-
analysis suggested that NSAIDs may prevent lung cancer,20
the heterogeneity of the pooled studies limits the interpret-
ability of this finding. Despite basic research showing that the
COX-2 pathway is involved in lung cancer development and
metastasis,21–24 experts are reluctant to suggest that wide-
spread use of NSAIDs will prevent lung cancer.25
For the current project, we considered important limi-
tations in previous studies: (1) most studies only looked at
aspirin use, and detailed analyses of nonaspirin NSAIDs were
seldom undertaken; (2) only four studies examined a high-
risk population,8–10,19 persons for whom the benefits of
*Veterans Affairs National Quality Scholars Program, Tennessee Valley
Healthcare System, Nashville, TN; Departments of †Biostatistics and
‡Medicine and Preventive Medicine, Vanderbilt University, Nashville, TN.
Funded by the NIH/NCI 1P50 CA90949-01 SPORE in Lung Cancer. Dr.
Wall was supported by the Office of Academic Affiliations, Department
of Veterans Affairs, VA National Quality Scholars Program, and with
resources at the VA Tennessee Valley Healthcare System, Nashville, TN.
Dr. Smalley was supported in part by the Agency for Healthcare Re-
search and Quality, Centers for Education and Research on Therapeutics
(grant HS1-0384).
Conflicts of interest: none.
Address for correspondence: Richard J. Wall, MD, MPH, Division of
Pulmonary and Critical Care Medicine, University of Washington, Box
359762, 325 Ninth Avenue, Seattle, WA 98104. E-mail: brickw@u.
washington.edu
Copyright © 2007 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/07/0202-0109
Journal of Thoracic Oncology • Volume 2, Number 2, February 2007 109
NSAID prophylaxis would theoretically be most evident; and
(3) only three studies objectively measured NSAID exposure
using computerized pharmacy databases.13,18,19 The remain-
ing studies relied on self-reporting by subjects, and several
studies followed subjects for many years after assessing
exposure only once.
We conducted a nested case-control study in a large,
statewide, population-based cohort to determine whether
nonaspirin NSAIDs are associated with a decreased risk of
lung cancer development. Using a detailed computerized
pharmacy database, we sought to objectively describe the
independent and combined effects of both cumulative NSAID
exposure and recent NSAID exposure. After looking at the
general population, we performed identical analyses in a sub-
group of high-risk individuals with chronic obstructive pul-
monary disease (COPD).
MATERIALS AND METHODS
The study protocol was reviewed and approved by the
Vanderbilt University Institutional Review Board. Before any
data analysis, a written protocol specified the steps for selec-
tion of cases and controls, ascertainment of exposure, and
definitions for all population variables.
Study Population
We performed a nested case-control study in the Ten-
nessee State Medicaid (TennCare) population. The coverage
period extended from January 1, 1990 through December 31,
2000. Any adult enrolled in TennCare during this period was
eligible for entry into the study source population, provided
they were at least 45 years old and continuously enrolled in
TennCare during the 5 years immediately before entry. The
latter requirement ensured that complete prescription drug
information was available for each individual in the 5 years
leading up to lung cancer diagnosis. A person remained in the
study population until the first of the following occurred: end
of study, diagnosis of lung cancer, death, or loss of TennCare
coverage for 30 days. We permitted lapses of coverage up
to 30 days. If a patient lost TennCare coverage for 30 days,
they could only re-enter the study once they had been con-
tinuously enrolled in TennCare for another 5 years. Exclusion
criteria included the presence, at entry into TennCare, of a
life-threatening disease (renal failure, liver failure, respira-
tory failure, human immunodeficiency virus infection, can-
cer other than nonmelanoma skin cancer) or previous organ
transplantation.
Data Sources
The TennCare research database has been used to
perform a variety of observational studies involving prescrip-
tion drug use and is composed of several administrative files.
An enrollment file identifies each individual and includes
their insurance eligibility status, dates of coverage, gender,
race, date of birth, and county of residence. Each hospital file
includes a patient identifier, dates of service, an admitting
diagnosis, and up to six discharge diagnoses recorded via the
International Classification of Diseases, Ninth Revision, Clin-
ical Modification (ICD-9) codes.26 Provider files note the date
of each encounter, a diagnosis (ICD-9), and procedures re-
corded using current procedural terminology codes.27 A phar-
macy file contains reimbursed prescriptions for all outpatients
and nursing home residents. The pharmacy file identifies the
date that the prescription was filled, which drug was dis-
pensed, how much of the drug was dispensed, and the number
of days of drug supplied.
Identification of Cases
Potential cases were identified by the presence of a
diagnosis for lung or bronchus cancer (ICD-9 codes 162.X) in
a hospital, emergency department, or outpatient claim. Be-
cause professional coders submit hospital and emergency
department claims, a single encounter with the appropriate
ICD-9 code qualified as a case. Because outpatient claims are
less reliable, two qualifying encounters separated by at least
7 days were required. For this latter group, the second code
was used for case verification; the date of the first code was
considered the cancer index date.
Identification of Controls
For each identified case, up to 10 matched controls
were randomly selected from the remaining source popula-
tion using risk-set sampling (i.e., all potential controls were
enrolled in TennCare on the index date). Matching was based
on gender, age (5 years), and calendar year of study entry.
In the rare situation in which fewer than 10 potential controls
were identified, all available controls meeting the matching
criteria were used. Based on this strategy, persons in the study
were theoretically eligible to be a control on more than one
occasion, and an individual could potentially (and appropri-
ately) serve both as a control and then later as a case.28
Exposure Ascertainment
Exposure to NSAIDs during the 5 years before the
index date was determined using the detailed TennCare
pharmacy file. Because previous studies suggest that cumu-
lative duration of NSAID exposure is important,17,29,30
NSAID exposure-days were determined for each person
based on the prescribed days supply. We further classified
these exposure-days into four categories (none, 12 months,
12–24 months, 25–60 months). To explore whether recent
NSAID use confers an independent protective effect,31 indi-
viduals with an NSAID prescription in the year before the
index date were classified as recent users.
Nearly all NSAIDs analyzed in this study were nonse-
lective COX inhibitors. The proportion of subjects taking
COX-2 inhibitors was very small because these medications
were not put on the TennCare formulary until 1999 (the final
year of our study). Overall, COX-2 inhibitors contributed
0.2% of all person-years analyzed in this study.
Measures of Comorbidity
Comorbid diseases were assessed by the presence of
respective medication prescriptions and by non-lung cancer
inpatient hospitalizations during the 5 years before the cancer
index date. Inpatient hospital days were totaled for the 5 years
before index date, then stratified into four categories: none,
1–7 days, 8–21 days, 21 days. Hospital days during the
year before index date were discounted if the primary dis-
charge diagnosis was a respiratory illness that might have
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potentially been an undetected lung neoplasm. Non-NSAID
prescription drugs in the past year were categorized as
gastrointestinal drugs, inhaled or oral corticosteroids, other
pulmonary drugs (e.g., inhaled -agonists), cardiac and anti-
hypertensive medications, diabetic medications, antibiotics,
non-NSAID analgesics, human immunodeficiency virus drugs,
anxiolytics and psychotropics, immunosuppressives, drugs used
to treat cough or cold symptoms, and “other” (not categorized
above) drugs.
High-Risk COPD Patients
Approximately 75% to 95% of patients with COPD
have a smoking history.32–34 However, COPD patients have
an increased risk of lung cancer that persists even after
adjustment for their tobacco exposure.35–37 Given the possi-
bility that NSAIDs may exert a greater protective effect in
these high-risk individuals and because COPD essentially
provides an indirect standardization for smoking, we iden-
tified all subjects with COPD using ICD-9 codes 491.X
(chronic bronchitis) or 492.X (emphysema) during the 5
years before index date. In a manner similar to case ascer-
tainment, we required a single code from the inpatient and
emergency department settings or two qualifying outpatient
codes. New COPD diagnoses during the year before the index
date were not counted; this avoided potential misclassifica-
tion of undetected lung neoplasms as COPD. We also created
a broader category of “smoking-related diagnoses” that in-
cluded COPD, prescription nicotine use, chronic sinusitis,
and chronic laryngitis.
Statistical Analysis
Descriptive characteristics were used to compare the
cases and controls, including demographics and measures of
health care use. To examine the relationship between NSAID
exposure and subsequent lung cancer development, control
for confounding, and determine whether effect modification
was present, we performed conditional logistic regression
using SAS (Cary, NC). In the primary logistic model for the
general population, subjects with no NSAID prescriptions
during the 5 years before the index date served as the referent
category. Similarly, subjects with no NSAID prescriptions
during the 5 years before the index date served as the referent
category in the second model (high-risk COPD patients).
Initial model terms included subject demographics
(age, gender, race, urban/rural), comorbidity measures (hos-
pital days in past 5 years, non-NSAID prescription drugs),
and indicators of COPD. The final model also included terms
for nursing home status and smoking-related diagnoses. Po-
tential confounders were selected based on a priori hypothe-
ses. We examined both the independent and combined influ-
ences of cumulative NSAID exposure and recent NSAID
exposure (i.e., within the past year) compared with individ-
uals with no NSAID exposure. Given the uncertainty about
this relationship and mixed results in previous studies, all p
values were two sided and values 0.05 considered statisti-
cally significant.
RESULTS
A total of 347,269 persons were initially eligible for
study. After excluding 43,870 persons for life-threatening
illnesses or organ transplantation, 303,399 persons were en-
rolled in the study population. Overall, a total of 3370 lung
cancer cases and 33,680 matched controls were identified
during the study period. Follow-up lasted a median 6.3 years,
and the population contributed a total of 1,900,000 person-
years of observation.
Descriptive characteristics of the study population are
presented in Table 1. Overall, both groups were similar with
regards to age, gender, race, urban or rural residence, and
nursing home status. With the exception of diabetes and
antihypertensive medications, cases were more likely to take
non-NSAID prescription medications, suggesting a higher
TABLE 1. Characteristics of Cases and Controls
% Controls
(n  33,680)
% Cases
(n  3370)
Age, y, mean (SD) 65.9 (10.4) 66.0 (10.4)
Female 49 49
Race
White 65.6 64.9
Black 22.4 21.2
Other/unknown 12 14
Residence
Urban 23.5 23.3
Suburban 47.7 46.2
Rural 28.8 30.5
Nursing home resident 9 7
Use of non-NSAID drug types
Diabetes 17.7 13.6
HIV 6.2 7.4
Antibiotics 71.6 76.8
Anxiolytics/psychotropics 55 60.2
Other drugs 81 85.7
Immunosuppressive 0.7 1
Gastrointestinal 41.6 49
Non-NSAID analgesics 59 68.2
Antihypertensive/cardiovascular 62.6 62.8
Other cardiovascular 41.6 46.9
Pulmonary 23.8 41.5
Corticosteroids 19.6 25.3
Nicotine 0.1 0.5
Diagnoses indicative of tobacco use
COPD 6 14.8
Smoking related diagnoses 7.9 18.3
Respiratory diagnoses 9.6 18.9
Cough, allergy, URI medications 19.7 23.1
Hospital days in past 5 y
None 46.1 35.5
1–7 20.7 22.4
8–21 18.8 23.4
21 14.4 18.6
NSAID, nonsteroidal anti-inflammatory drug; HIV, human immunodeficiency
virus; COPD, chronic obstructive pulmonary disease; URI, upper respiratory infection.
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number of comorbid conditions. Cases were more likely to
have COPD or diagnoses or treatments indicative of smoking
and to have been hospitalized during the 5 years before the
cancer index date.
Table 2 shows the various patterns of NSAID use and
the odds of developing lung cancer in the general population.
Overall, cases were slightly more likely than controls to have
an NSAID prescription in the 5 years before the cancer index
date (64% versus 59%, respectively). In this primary model,
there was no statistically significant association between
NSAID exposure and lung cancer development (overall crude
odds ratio  1.24, 95% confidence interval: 1.16–1.34;
overall adjusted odds ratio  1.03, 95% confidence interval:
0.94–1.12). Furthermore, no statistically significant associa-
tion was noted for any of the individual exposure strata. This
finding did not vary after considering recent NSAID exposure
(i.e., within the past year) or cumulative NSAID exposure
during the previous 5 years. The association between NSAID
use and lung cancer appeared to be confounded by tobacco
use. Among those with a smoking-related diagnosis, 70% had
received a prescription for NSAIDs in the previous 5 years,
whereas among those without a smoking-related diagnosis,
only 58% had received NSAIDs (p  0.001).
We identified a total of 2519 subjects with COPD.
Table 3 shows the patterns of NSAID use and the odds of
developing lung cancer in this high-risk COPD population.
Overall, there was no statistically significant association be-
tween lung cancer development and NSAID exposure in the
adjusted analyses. This finding did not vary after considering
recent or cumulative NSAID exposure.
DISCUSSION
This study failed to demonstrate a protective effect of
NSAIDs on the development of lung cancer. Despite colo-
rectal cancer studies suggesting that the protective effects of
NSAIDs may depend on both cumulative exposure and recent
use,31 we found no protective effect in any exposure strata.
When we repeated our analyses in a subset of high-risk
individuals with COPD, in which confounding by smoking
would be mitigated because the vast majority have a smok-
ing history, we found no significant effect associated with
NSAID use.
The main strengths of this population-based study are
its size and systematic ascertainment of NSAID exposure. By
identifying more than 3300 cases, we have performed the
largest published case-control study examining the relation-
ship between NSAIDs and lung cancer. By nesting the study
in a well-defined statewide population, we avoided selection
biases that occur when case-control studies are conducted
among hospitalized patients. The use of computerized phar-
macy files to ascertain NSAID exposure eliminated the po-
tential recall biases common to studies that rely on self-
reported data and allowed us to quantify NSAID exposure
more precisely.
In contrast to our study, a recent meta-analysis of 14
studies (eight cohort, six case-control) suggested that NSAIDs
may prevent lung cancer.20 However, the studies in this
meta-analysis demonstrated significant heterogeneity in their
results, thereby raising questions about whether the studies
should be combined into one summary statistic.38 In addition,
the 14 studies used different patient populations (hospitalized
versus outpatient), exposures (aspirin versus nonaspirin
NSAIDS versus both), and follow-up times. Finally, none of
the studies was a randomized clinical trial, and meta-analyses
are generally less helpful when combining observational
studies.39 When the authors performed several exploratory
subgroup analyses, the only analysis that did not reveal
significant heterogeneity was for the eight cohort studies.
However, none of these studies objectively measured NSAID
exposure. Overall, we believe that this meta-analysis does not
definitively answer the question at hand.
The current study has important limitations. First, while
the pharmacy file is an accurate measure of prescription drug
dispensing, it provides no information on compliance or use
of nonprescription NSAIDs. This resulting nondifferential
exposure misclassification might result in a conservative bias
and obscure an association of small magnitude. Conversely,
our previous experiences suggest that most patients in this
Medicaid population are reluctant to pay for over-the-counter
NSAIDs on an ongoing basis because prescription NSAIDs
are free. Second, we used diagnostic codes to identify cases
and did not have pathologic verification. To reduce our
chances of misclassification, our protocol required at least
one inpatient lung cancer diagnosis or two separate outpatient
TABLE 2. Patterns of NSAID Use and Odds of Lung Cancer Development in the General Population
Recent Use
(in past year)
Cumulative Use
(in past 5 y) Cases (%) Controls (%) Crude OR 95% CI Adj. ORa 95% CIa
No None 36.3 41.5 Ref. — Ref. —
12 mo 23.2 22.2 1.16 1.06–1.28 0.93 0.83–1.03
12–24 mo 2.6 2.2 1.36 1.08–1.72 1.06 0.83–1.35
25–60 mo 0.9 0.8 1.27 0.86–1.97 1.00 0.67–1.49
Yes 12 mo 22.4 17.8 1.45 1.32–1.60 1.17 1.05–1.31
12–24 mo 6.4 6.2 1.19 1.02–1.38 0.96 0.81–1.13
25–60 mo 8.3 8.3 1.15 1.01–1.32 0.96 0.82–1.11
a Adjusted for age, gender, nursing home status, smoking-related diagnoses, and use of non-NSAID prescription drugs.
NSAID, nonsteroidal anti-inflammatory drug; Adj. OR, adjusted odds ratio; CI, confidence interval.
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diagnoses. We previously found the positive predictive value
of a similar strategy for identifying colon cancer cases in this
population to be 80%,31 and we expect it be at least as high
for a generally fatal cancer like lung cancer. Third, diagnostic
uncertainty of ICD-9 codes could have also affected the
identification of high-risk COPD subjects. However, lack of
full ascertainment of every TennCare patient with COPD
would not likely affect an association between NSAID use
and lung cancer.
Another important limitation is that we had no infor-
mation about tobacco exposure. Smoking is by far the most
important risk factor for developing lung cancer, and NSAID
users were more likely to have a smoking-related diagnosis,
suggesting that smoking may confound the relationship be-
tween NSAID use and lung cancer. Although we attempted to
indirectly adjust for smoking by using a collection of smok-
ing-related illnesses, there is a potential for residual con-
founding because we did not directly measure tobacco expo-
sure. Conversely, our analyses of high-risk COPD subjects
were much less susceptible to this unmeasured confounding,
and we still did not find a statistically significant relationship
in any exposure stratum. More reliable information will come
from future studies in which detailed smoking histories can
assess whether smoking truly confounds the relationship
between NSAIDs and lung cancer.
Because there is no widely accepted and effective
screening strategy for preventing lung cancer death, the
concept of chemoprevention remains attractive. Such a che-
mopreventive strategy, however, will need to be both effec-
tive and safe. Although the most definitive information would
come from a randomized, controlled trial of NSAIDs to
prevent lung cancer, previous trials have already failed to
demonstrate a beneficial effect using agents that were pre-
sumably safer than traditional NSAIDs, such as -carotene.40
Given the well-known toxicity of NSAIDs, including COX-II
inhibitors,41,42 the use of NSAIDs for primary prevention of
lung cancer in a controlled trial setting should be approached
with caution. In addition, recent animal models suggest that
although COX inhibitors attenuate pulmonary inflammation,
these agents may also paradoxically increase tumorigenesis
and tumor burden.43 Overall, the complex relationships be-
tween COX and various inflammatory/tumorigenic mediators
remain poorly understood.
In summary, this large population-based study in a
well-defined statewide population found no protective effect
from NSAIDs on the development of lung cancer. This
finding persisted regardless of the cumulative duration of
NSAID exposure, recent NSAID exposure, or the presence of
COPD.
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